[PTLA] Portola Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 25.06 Change: 6.33 (33.8%)
Ext. hours: 24.85 Change: -0.21 (-0.84%)

chart PTLA

Refresh chart

Strongest Trends Summary For PTLA

PTLA is in the long-term down -65% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -2.28% Sales Growth - Q/Q-2.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.53% ROE-36.59% ROI
Current Ratio9.89 Quick Ratio Long Term Debt/Equity Debt Ratio0.1
Gross Margin Operating Margin-1592.24% Net Profit Margin-1595.01% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities113.04 M Cash From Investing Activities9.44 M Cash From Operating Activities-47.15 M Gross Profit
Net Profit-46.91 M Operating Profit-46.5 M Total Assets486.3 M Total Current Assets403.45 M
Total Current Liabilities40.79 M Total Debt Total Liabilities67.32 M Total Revenue2.36 M
Technical Data
High 52 week37.76 Low 52 week15.46 Last close30.94 Last change1.91%
RSI68.73 Average true range1.39 Beta1.71 Volume8.33 M
Simple moving average 20 days15.82% Simple moving average 50 days15.78% Simple moving average 200 days14.08%
Performance Data
Performance Week24.76% Performance Month18.27% Performance Quart-2.7% Performance Half8.41%
Performance Year-17.97% Performance Year-to-date58.5% Volatility daily3.23% Volatility weekly7.23%
Volatility monthly14.81% Volatility yearly51.32% Relative Volume1513.75% Average Volume1.04 M
New High New Low

News

2020-01-17 13:25:08 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA

2020-01-17 12:04:00 | PORTOLA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

2020-01-17 12:00:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Portola Pharmaceuticals, Inc. Investors

2020-01-17 10:22:13 | Portola Pharmaceuticals Shareholder Alert - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors of Portola Pharmaceuticals – Class Action Filed Against PTLA

2020-01-17 09:07:00 | EQUITY ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Portola Pharmaceuticals, Inc. – PTLA

2020-01-16 22:07:00 | Glancy Prongay & Murray LLP Files First Securities Class Action on Behalf of Portola Pharmaceuticals, Inc. Investors

2020-01-14 16:03:00 | INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Portola Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm

2020-01-10 18:41:00 | The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Portola Pharmaceuticals, Inc., PTLA

2020-01-10 17:24:00 | Lost Money in Portola Pharmaceuticals, Inc.?

2020-01-10 16:15:00 | PTLA LOSSES ALERT: Bernstein Liebhard LLP Announces an Investigation into Portola Pharmaceuticals Inc., and Encourages Investors with Losses to Contact the Firm

2020-01-10 15:30:00 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors

2020-01-10 15:19:58 | Portola Pharmaceuticals Slump Ignites Heavy Call Trading

2020-01-10 13:57:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors

2020-01-10 12:03:00 | PTLA Alert: Johnson Fistel Launches Investigation into Portola Pharmaceuticals; Investors Encouraged to Contact Firm

2020-01-10 10:01:00 | Portola's stock falls on weak Andexxa sales

2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

2020-01-09 16:01:00 | Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million

2019-12-23 08:30:00 | Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

2019-12-17 08:30:00 | Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke

2019-12-10 12:06:10 | Why health care innovation is where investors should look

2019-12-09 15:21:00 | Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

2019-12-09 09:52:46 | Should You Buy Portola Pharmaceuticals Inc PTLA?

2019-12-08 12:00:00 | Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

2019-11-15 16:25:00 | Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

2019-11-08 11:31:04 | Pacira's PCRX Q3 Earnings Top Estimates, Revenues Rise Y/Y

2019-11-07 09:22:11 | Portola Pharmaceuticals, Inc. NASDAQ:PTLA: Is Breakeven Near?

2019-11-06 11:35:26 | Edited Transcript of PTLA earnings conference call or presentation 5-Nov-19 9:30pm GMT

2019-11-06 10:41:03 | Mallinckrodt MNK Q3 Earnings Beat, Stock Down on Sales Miss

2019-11-06 10:07:00 | Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology ASH Annual Meeting

2019-11-05 18:05:11 | Portola Pharmaceuticals PTLA Reports Q3 Loss, Tops Revenue Estimates

2019-11-05 16:00:00 | Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-11-05 11:17:04 | Bausch BHC Beats on Q3 Earnings & Sales, Raises Guidance

2019-11-05 10:42:03 | Endo ENDP Q3 Earnings & Revenues Beat Estimates, Down Y/Y

2019-11-01 16:30:00 | Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-11-01 11:07:03 | WIll Allergan AGN Beat Estimates This Earnings Season?

2019-10-30 12:01:04 | Guardant Health GH to Report Q3 Earnings: What's in Store?

2019-10-29 10:33:02 | Portola Pharmaceuticals PTLA Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-10-29 09:46:01 | Catalyst Pharma CPRX to Post Q3 Earnings: What's in Store?

2019-10-28 09:59:23 | Portola Pharmaceuticals Inc PTLA: Are Hedge Funds Right About This Stock?

2019-10-28 09:38:01 | Sony SNE to Report Q2 Earnings: What's in the Offing?

2019-10-28 09:00:00 | Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding

2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

2019-10-15 08:30:00 | Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

2019-09-19 08:20:00 | Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

2019-08-22 08:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

2019-08-16 11:08:39 | Here's Why Portola Pharmaceuticals NASDAQ:PTLA Can Afford Some Debt

2019-08-13 19:32:00 | Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock

2019-08-13 07:25:15 | The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

2019-08-12 16:43:00 | Portola Pharmaceuticals Announces Proposed Offering of Common Stock